AR107800A1 - Proceso para la preparación de un conjugado de anticuerpo-rifamicina - Google Patents
Proceso para la preparación de un conjugado de anticuerpo-rifamicinaInfo
- Publication number
- AR107800A1 AR107800A1 ARP170100538A ARP170100538A AR107800A1 AR 107800 A1 AR107800 A1 AR 107800A1 AR P170100538 A ARP170100538 A AR P170100538A AR P170100538 A ARP170100538 A AR P170100538A AR 107800 A1 AR107800 A1 AR 107800A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- preparation
- otf
- compound
- reacting
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 229960003292 rifamycin Drugs 0.000 title 1
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- MDCULZTYOKLIGU-UHFFFAOYSA-N 2-amino-5-fluorobenzene-1,3-diol Chemical compound Nc1c(O)cc(F)cc1O MDCULZTYOKLIGU-UHFFFAOYSA-N 0.000 abstract 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 abstract 2
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 abstract 2
- -1 lithium bis (trimethylsilylamide) diisopropylamide Chemical compound 0.000 abstract 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 abstract 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 abstract 2
- VNNDVNZCGCCIPA-FDGPNNRMSA-N (z)-4-hydroxypent-3-en-2-one;manganese Chemical compound [Mn].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O VNNDVNZCGCCIPA-FDGPNNRMSA-N 0.000 abstract 1
- PWRFDGYYJWQIAB-UHFFFAOYSA-N 1,3,5-trifluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=C(F)C=C1F PWRFDGYYJWQIAB-UHFFFAOYSA-N 0.000 abstract 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 abstract 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910004882 Na2S2O8 Inorganic materials 0.000 abstract 1
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 abstract 1
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 abstract 1
- 150000004703 alkoxides Chemical class 0.000 abstract 1
- 239000012080 ambient air Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229960004217 benzyl alcohol Drugs 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- FJDJVBXSSLDNJB-LNTINUHCSA-N cobalt;(z)-4-hydroxypent-3-en-2-one Chemical compound [Co].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O FJDJVBXSSLDNJB-LNTINUHCSA-N 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 abstract 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 abstract 1
- 239000011592 zinc chloride Substances 0.000 abstract 1
- 235000005074 zinc chloride Nutrition 0.000 abstract 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
- C07C215/78—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen procesos para la preparación de F-benzoxazinorifamicina y compuestos intermedios para la conjugación con un anticuerpo. Reivindicación 1: Un proceso para la preparación de F-benzoxazinorifamicina de fórmula (1), que comprende hacer reaccionar rifamicina S de fórmula (2), 2-amino-5-fluorobenceno-1,3-diol de fórmula (3), y uno o más oxidantes seleccionados entre TEMPO y los análogos de TEMPO, aire ambiente, oxígeno gaseoso, benzoquinona, óxido de manganeso (MnO₂), (PhI(OTs)OH, peryodato de sodio (NalO₄), cloranilo, peróxido de hidrógeno, Fe₂O₃, Na₂S₂O₈, Co(acac)₃, Mn(acac)₂, Cu(OAc)₂, CuO, CuBr₂, ZnCl₂, InCl₃, Ag(OTf)₂, Sc(OTf)₃, e Yb(OTf)₃, para formar el compuesto de fórmula (1). Reivindicación 18: Un proceso para la preparación de 2-amino-5-fluorobenceno-1,3-diol de fórmula (3), que comprende: (a) hacer reaccionar 1,3,5-trifluoro-2-nitrobenceno de fórmula (4), fenilmetanol, y un reactivo básico seleccionado entre bis(trimetilsililamida)diisopropilamida de litio, y un reactivo alcóxido, para formar (((5-fluoro-2-nitro-1,3- fenilen)bis(oxi))bis(metilen))dibenceno de fórmula (5); y (b) hacer reaccionar el compuesto de fórmula (5) con hidrógeno gaseoso y un catalizador metal heterogéneo para formar el compuesto de fórmula (3).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662303556P | 2016-03-04 | 2016-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107800A1 true AR107800A1 (es) | 2018-06-06 |
Family
ID=58361102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100538A AR107800A1 (es) | 2016-03-04 | 2017-03-03 | Proceso para la preparación de un conjugado de anticuerpo-rifamicina |
Country Status (13)
Country | Link |
---|---|
US (2) | US10336683B2 (es) |
EP (1) | EP3423457B1 (es) |
JP (2) | JP6705904B2 (es) |
KR (1) | KR102204805B1 (es) |
CN (1) | CN108713020A (es) |
AR (1) | AR107800A1 (es) |
AU (1) | AU2017228468B2 (es) |
BR (1) | BR112018014355A2 (es) |
CA (1) | CA3012046C (es) |
IL (1) | IL260465B (es) |
MX (1) | MX2018010491A (es) |
SG (1) | SG11201807537RA (es) |
WO (1) | WO2017152083A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3012046C (en) | 2016-03-04 | 2020-11-10 | Genentech, Inc. | Process for the preparation of an antibody-rifamycin conjugate |
CN108047250B (zh) * | 2018-02-12 | 2020-08-14 | 丹诺医药(苏州)有限公司 | 一种利福霉素-硝基咪唑偶联分子的应用 |
CN110687217B (zh) * | 2018-08-07 | 2021-04-23 | 中国科学院大连化学物理研究所 | 液相色谱测定利福霉素s的方法 |
CN110687218B (zh) * | 2018-08-07 | 2021-04-23 | 中国科学院大连化学物理研究所 | 液相色谱测定苯并噁嗪利福霉素的方法 |
EP3897841A1 (en) * | 2018-12-21 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
EP4387618A1 (en) * | 2021-08-20 | 2024-06-26 | Rutgers, the State University of New Jersey | Dual-targeted rna polymerase inhibitors: conjugates of benzoxazino- and spiro-rifamycins with n?-aroyl- n-aryl-phenylalaninamides |
CN114436864A (zh) * | 2022-02-17 | 2022-05-06 | 浙江鼎龙科技股份有限公司 | 一种2-甲基-5氨基苯酚的制备方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB877732A (en) | 1958-08-12 | 1961-09-20 | Lepetit Spa | The antibiotic rifomycin, its components and methods of preparing same |
US4690919A (en) | 1984-01-04 | 1987-09-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
JPS63183587A (ja) | 1985-02-05 | 1988-07-28 | Kanegafuchi Chem Ind Co Ltd | ベンゾキサジノリフアマイシン誘導体 |
CA1304363C (en) | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
MXPA06002088A (es) | 2003-08-22 | 2006-08-11 | Activbiotics Inc | Analogos de rifamicina y usos de los mismos. |
US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
EP1701962A4 (en) | 2003-12-23 | 2008-03-05 | Activbiotics Inc | RIFAMYCIN ANALOGS AND USES THEREOF |
US7265107B2 (en) | 2004-03-10 | 2007-09-04 | Cumbre Pharmaceuticals Inc. | Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
CN101395259A (zh) | 2005-12-14 | 2009-03-25 | 活跃生物药物学有限公司 | 利福霉素类似物及其应用 |
US7678791B2 (en) | 2006-07-12 | 2010-03-16 | Cumbre Ip Ventures, L.P. | Nitroheteroaryl-containing rifamycin derivatives |
DK2121920T3 (da) | 2007-03-01 | 2011-11-21 | Symphogen As | Fremgangsmåde til kloning af sammenhørende antistoffer |
WO2008141044A2 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
RU2505544C2 (ru) | 2007-10-19 | 2014-01-27 | Дженентек, Инк. | Антитела против tenb2, сконструированные с цистеином, и конъюгаты антитело - лекарственное средство |
WO2009064792A1 (en) | 2007-11-16 | 2009-05-22 | Cumbre Pharmaceuticals Inc. | Quinolone carboxylic acid-substituted rifamycin derivatives |
EP2234954B1 (en) * | 2007-12-20 | 2015-02-18 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
EP2324041A4 (en) | 2008-08-13 | 2012-06-13 | Targanta Therapeutics Corp | PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS |
US9000130B2 (en) | 2010-06-08 | 2015-04-07 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20150147328A1 (en) | 2012-05-07 | 2015-05-28 | Mogam Biotechnology Institute | Vaccine composition for preventing staphyllococcus aureus infection |
JP6371758B2 (ja) | 2013-03-12 | 2018-08-08 | 全薬工業株式会社 | 抗ブドウ球菌抗体、その製造方法並びにその使用 |
US20140356375A1 (en) * | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
PT3004162T (pt) | 2013-05-31 | 2020-05-27 | Genentech Inc | Anticorpos e conjugados anti-parede teicoica |
US9884126B2 (en) | 2013-05-31 | 2018-02-06 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
EP3226908A1 (en) * | 2014-12-03 | 2017-10-11 | F.Hoffmann-La Roche Ag | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
EP3226911A1 (en) * | 2014-12-03 | 2017-10-11 | F.Hoffmann-La Roche Ag | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
CA3012046C (en) | 2016-03-04 | 2020-11-10 | Genentech, Inc. | Process for the preparation of an antibody-rifamycin conjugate |
-
2017
- 2017-03-03 CA CA3012046A patent/CA3012046C/en not_active Expired - Fee Related
- 2017-03-03 JP JP2018540460A patent/JP6705904B2/ja not_active Expired - Fee Related
- 2017-03-03 KR KR1020187027989A patent/KR102204805B1/ko active IP Right Grant
- 2017-03-03 MX MX2018010491A patent/MX2018010491A/es unknown
- 2017-03-03 SG SG11201807537RA patent/SG11201807537RA/en unknown
- 2017-03-03 US US15/448,894 patent/US10336683B2/en not_active Expired - Fee Related
- 2017-03-03 AR ARP170100538A patent/AR107800A1/es unknown
- 2017-03-03 AU AU2017228468A patent/AU2017228468B2/en not_active Ceased
- 2017-03-03 CN CN201780014867.4A patent/CN108713020A/zh active Pending
- 2017-03-03 WO PCT/US2017/020711 patent/WO2017152083A1/en active Application Filing
- 2017-03-03 EP EP17712298.3A patent/EP3423457B1/en active Active
- 2017-03-03 BR BR112018014355-3A patent/BR112018014355A2/pt not_active Application Discontinuation
-
2018
- 2018-07-08 IL IL260465A patent/IL260465B/en active IP Right Grant
-
2019
- 2019-05-17 US US16/415,612 patent/US10689325B2/en not_active Expired - Fee Related
-
2020
- 2020-01-07 JP JP2020000874A patent/JP2020090506A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6705904B2 (ja) | 2020-06-03 |
KR20180118173A (ko) | 2018-10-30 |
IL260465B (en) | 2020-11-30 |
EP3423457B1 (en) | 2021-02-17 |
SG11201807537RA (en) | 2018-09-27 |
KR102204805B1 (ko) | 2021-01-20 |
US20170252457A1 (en) | 2017-09-07 |
AU2017228468A1 (en) | 2018-07-26 |
BR112018014355A2 (pt) | 2018-12-18 |
US10689325B2 (en) | 2020-06-23 |
JP2019510740A (ja) | 2019-04-18 |
EP3423457A1 (en) | 2019-01-09 |
CA3012046C (en) | 2020-11-10 |
CN108713020A (zh) | 2018-10-26 |
AU2017228468B2 (en) | 2019-12-05 |
JP2020090506A (ja) | 2020-06-11 |
WO2017152083A1 (en) | 2017-09-08 |
US10336683B2 (en) | 2019-07-02 |
US20190270695A1 (en) | 2019-09-05 |
MX2018010491A (es) | 2018-11-09 |
CA3012046A1 (en) | 2017-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR107800A1 (es) | Proceso para la preparación de un conjugado de anticuerpo-rifamicina | |
Voutyritsa et al. | Organocatalytic oxidation of substituted anilines to azoxybenzenes and nitro compounds: mechanistic studies excluding the involvement of a dioxirane intermediate | |
Besnard et al. | On the spontaneous carboxylation of 1-butyl-3-methylimidazolium acetate by carbon dioxide | |
CO6430455A2 (es) | Proceso para la producción de compuestos de ácido quetomalónico o sus hidratos | |
FI3587400T3 (fi) | Menetelmä pde4:n estäjän valmistamiseksi | |
AR073865A1 (es) | Un metodo para producir sulfuro de litio. | |
GB1484513A (en) | Polyphenylene ether copolymers | |
AR092001A1 (es) | Proceso para la prodccion de compuestos quimicos a partir de dioxido de carbono | |
RU2014152878A (ru) | Катализатор для получения высших спиртов | |
Wang et al. | Synthesis of cyclic carbonates from CO 2 and epoxides catalyzed by low loadings of benzyl bromide/DMF at ambient pressure | |
ES2055824T3 (es) | Emulsionantes y un procedimiento para la obtencion de dispersiones polimeras homodispersas y gruesamente divididas con empleo de estos emulsionantes. | |
WO2015082422A3 (en) | Process for reacting chemical compounds | |
KR20170094118A (ko) | 카르복실산 에스테르의 제조 방법 | |
CO2018007613A2 (es) | Sistema de depuración de dióxido de azufre y proceso para la producción de productos de potasio | |
IN2014DN07290A (es) | ||
CL2018003057A1 (es) | Uso de una composición de sal de nitrato como un medio de transferencia de calor o almacenamiento de calor para la primera operación de un aparato que contiene estos medios. | |
Mamone et al. | Reactivity of carbon dioxide in hydrofluoroethers: a facile access to cyclic carbonates | |
Luo et al. | Oxidation of alcohols to carbonyl compounds with molecular iodine in the presence of potassium tert-butoxide | |
Uchida et al. | Gas-phase ozone reactions with Z-3-hexenal and Z-3-hexen-1-ol: Formation yields of OH radical, propanal, and ethane | |
Chowdhury et al. | Manganese (III)-Based Oxidative Radical Cyclization of Terminal Alkadienes with N, N'-Bis (3-oxobutanoyl)-α, ω-alkanediamines. Formation of Macrodiamides | |
Dossmann et al. | Formation and Characterization of Gaseous Adducts of Carbon Dioxide to Magnesium,(CO2) MgX−(X= OH, Cl, Br) | |
RU2012143346A (ru) | Способ получения трис (перфторалкил) фосфиноксиды | |
US9586926B2 (en) | Methods of making alkylene carbonates and methods of converting CO2 | |
WO2008083635B1 (en) | A method for the preparation of montelukast | |
Antoniotti et al. | Facile preparation of metallic triflates and triflimidates by oxidative dissolution of metal powders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |